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ABSTRACT 
Neurological symptoms related to microthrombosis are the hallmark of acute manifestations of 
acquired thrombotic thrombocytopenic purpura. Despite the achievement of hematological 
remission, patients may report persisting neurological impairment that affects their quality of life. 
To assess the long-term neuropsychological consequences of acute thrombotic thrombocytopenic 
purpura, we recruited 35 acquired thrombotic thrombocytopenic purpura patients (77% females, 
median age at onset 41 years, interquartile range 35-48) regularly followed at our out-patient clinic 
of thrombotic microangiopathies in Milan (Italy) from December 2015 to October 2016. Patients 
underwent a psychological evaluation of memory and attentional functions, emotional wellbeing 
and health-related quality of life at least 3 months after their last acute thrombotic 
thrombocytopenic purpura event (median 36 months, interquartile range 17-54). During the 
psychological consultation, 17 patients (49%) referred persisting subjective neurological 
impairment in the frame of a remission phase, with at least one symptom as disorientation, loss of 
concentration, dizziness, lack of balance, headache and diplopia. Neuropsychological assessment 
revealed lower scores than the Italian general population pertaining to direct, indirect and deferred 
memory. A higher degree of impairment of memory domains was found in patients with 
neurological involvement at the time of presentation of the first acute thrombotic thrombocytopenic 
purpura episode. Anxiety and depression were detected in 7 (20%) and 15 (43%) patients, 
respectively. Health-related quality of life was lower than the Italian general population, with mental 
domains more impacted than physical domains (mean difference 58.43, 95% confidence interval 
[-71.49, -45.37]). Our study demonstrates compromised memory and attention functions, persisting 
anxiety/depression symptoms and a generally reduced quality of life in patients surviving from 
acute acquired thrombotic thrombocytopenic purpura. New clinical strategies should be considered 
to improve these symptoms. 
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INTRODUCTION 
Thrombotic thrombocytopenic purpura (TTP) is a rare multisystem microangiopathy with fluctuating 
signs and symptoms. Its mortality rate could reach 90% when patients were left untreated, but it is 
reduced to 10% if patients are properly treated in the first 24 hours after diagnosis. Recovery is 
usually complete, but with a risk of relapse and the uncommon occurrence of persistent neurologic, 
cardiac and renal abnormalities.1 After recovery, despite of normal physical examination and 
laboratory data, many patients complain difficulties with memory, headache, loss of concentration 
and endurance, as expressed at patient support group meetings. Some attempts to quantify those 
neurological deficits in acquired TTP patients have been made in the context of small 
observational studies, but without taking into account a whole assessment of cognitive, emotional 
and health-related quality of life (HrQoL) dimensions.2-3 Cognitive domains required for complex 
attention, concentration skills and high level memory functions may be involved in patients with 
TTP due to diffuse microvascular subcortical lesions, similarly to neurologically normal individuals 
with untreated hypertension, sickle cell disease and multi-infarct dementia. Two widely accepted 
measures to evaluate HrQoL are the Short-Form 36 (SF-36)4 and the EuroQol 5D (EQ-5D).5 They 
are self-reported scales providing a numerical score to identify the level of perceived health status. 
For their generic nature, the SF-36 and the EQ-5D are frequently used in chronic conditions (e.g., 
haemophilia) and are applicable to many diseases.  
With this background and gaps of knowledge, we set up a study in order to investigate persistent 
cognitive abnormalities, emotional wellbeing and quality of life in patients who had recovered from 
an acute episode of acquired TTP. We also analyzed whether or not the presence of neurological 
involvement during the acute phase of TTP or severe ADAMTS13 deficiency during disease 
remission were related to persistent neurocognitive defects. Finally, we investigated whether there 
was an association between the emotional status of the patients and their quality of life. 
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METHODS 
Patients 
We performed a cross-sectional study of 35 patients with acquired TTP regularly followed at our 
out-patient clinic of thrombotic microangiopathies in Milan (Italy). Patients were enrolled at least 
three months after their last acute TTP event (median time of 36 months, interquartile range 17-54) 
from December 2015 to October 2016, when they underwent a comprehensive neuropsychological 
evaluation including memory and attentional functions, emotional wellbeing and HrQoL. 
Demographic and clinical variables were recorded, including age, sex, ethnicity, job status, level of 
education, clinical and biochemical data at the time of acute TTP (neurological involvement, 
platelet count and haemoglobin level at presentation, number of plasma exchange procedures 
required to attain remission), and plasma ADAMTS13 activity levels at the time of the 
neuropsychological assessment (± 3 months). Enrolment criteria are described in the Online 
Supplementary Appendix (Supplementary Table S1).  
Written informed consent was obtained from all subjects with approval of the Ethics Committee of 
Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, in accordance with the Declaration 
of Helsinki. 
 
Neurocognitive, emotional and HrQoL assessments 
Neurocognitive and psychological assessments were administered by a board-certified 
psychologist in standardized fashion in the frame of a single assessment session, which required 
approximately 1 hour to be completed, and included a test battery measuring two major cognitive 
domains, memory and attention6-8, the Hamilton Depression (HAM-D)9 and Anxiety (HAM-A)10 
rating scales for emotional wellbeing, and the Short-Form (SF) 364 form for HrQoL (Online 
Supplementary Appendix, Supplementary Table S2).  
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Statistical analysis  
Descriptive statistics were used for demographic, clinical and laboratory characteristics. 
Categorical variables were expressed as counts and percentages, continuous variables as means 
or medians with standard deviation (SD) or interquartile ranges (IQR). With regards to 
neuropsychological and HrQoL analyses, each subject’s raw score on each test was converted to 
a standardized score based on normative data generated from the value of the normal population 
according to the subject’s age and education level, as appropriate.11-15 Standardized scores of TTP 
patients were then compared with norm-referenced data from the Italian population11-15 by 
calculating the difference of means with 95% confidence intervals (CI) using unpaired and paired t-
tests. Similarly, difference of means with 95%CI from unpaired and paired t-tests were used to 
compare neurocognitive assessment results in acquired TTP patients with and without neurological 
manifestations during the first acute episode of TTP, and with and without reduced ADAMTS13 
activity during disease remission, close to the neuropsychological evaluation. For this analysis, an 
ADAMTS13 activity cut-off of 45% was used (i.e., the lower limit of the normality range in our 
ADAMTS13 activity assays). With regards to HrQoL, a standardized score of 50 was considered 
the cut-off for an acceptable quality of life.15-16 Finally, non-parametric correlation analyses were 
performed to evaluate the relationship between the results of emotional wellbeing tests and those 
of neurocognitive assessments or aggregated HrQoL scales. 
Statistical analyses were performed by SPSS, release 25.0 (IBM Corp., Armonk, NY, USA), and 
GraphPad Prism, version 7.03 (GraphPad Software, La Jolla California USA). 
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RESULTS 
Between December 2015 and October 2016, forty-one acquired TTP patients were approached for 
participating in the study during a follow-up visit at our out-patient clinic of thrombotic 
microangiopathy. Of them, one patient refused to participate and one patient was excluded owing 
to a pre-existing psychiatric disease. Four were not constantly attended at our center, and 
therefore they were excluded from the study. Thus, 35 patients were included in the study and 
underwent psychological tests and neurocognitive examinations (Supplementary File Online). 
Patient characteristics are reported in Table 1. All but one patient were Caucasian, with a female to 
male ratio of about 3:1 and a median age at TTP onset of 41 years (IQR 35-48). At the time of 
neuropsychological evaluation, 10 (29%) of 35 patients had suffered from recurrent TTP bouts. 
Twenty-two patients (63%) presented with neurological signs and symptoms at presentation of the 
first acute TTP episode (including coma [n=2], focal neurological signs [n=12], personality changes 
[n=2], transient ischemic attack [n=4], seizures [n=1], stroke [n=3]). During the psychological 
consultation, 17 (49%) patients reported persisting subjective neurological impairment in the 
remission phase, with at least one symptom as disorientation, loss of concentration, dizziness, lack 
of balance (unable to control and maintain the body position all the time) headache, and diplopia. 
 
Results of neurocognitive assessment 
At the digit span test, 25 (71%) and 23 (66%) patients had a scoring lower than the mean of the 
general population in direct (mean difference -1.26, 95%CI [-1.64, -0.87]) and backward (mean 
difference -1.49, 95%CI [-2.02, -0.96]) memory, respectively (Table 2). Similarly, lower scores in 
TTP patients were observed in the Rey List tests for both direct (mean difference -5.87, 95%CI 
[-8.57, -3.17]) and deferred memory (mean difference -1.67, 95%CI [-2.32, -1.02]). 
With regards to the attention domain, TTP patients were slower in performing the trail making B 
test (sustained and divided attention) in comparison with the general population (mean difference 
65.09 seconds, 95%CI [47.23, 82.94]). Conversely, patients were slightly faster in performing the 
trail making A test, which measures focused attention (mean difference -10.63 seconds, 95%CI 
[-15.81, -5.44]).  
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When we analyzed scores of neurocognitive assessments in patients with and without neurological 
signs and symptoms at presentation of the first acute TTP episode, we observed a higher degree 
of impairment in the memory domains of the first group of patients in 3 out of 4 memory tests (Digit 
span [direct]: mean difference -0.78, 95%CI [-1.54, -0.02]; Digit span [backward]: mean 
difference -0.90, 95%CI [-1.96, 0.17]; Rey word list [deferred]: mean difference -1.39, 95%CI [-
2.65, -0.13] (Table 3).  
No differences in neuropsychological assessments were found between patients with ADAMTS13 
activity levels during remission below and above 45% (Table 4). 
 
Results of emotional assessment 
TTP patients presented a mean level of anxiety with the HAM-A of 9.6 (SD=8.1) and a mean level 
of depression with the HAM-D of 7.4 (SD=5.7). The presence of clinical anxiety (HAM-A score > 
13) was detected in 7 (20%) of interviewed patients, while the presence of clinical depression 
(HAM-D score > 7) was present in 15 (43%) of them. All 7 patients with clinical anxiety presented 
concomitant clinical depression. Five (14%) patients showed a severe anxiety (HAM-A score > 24) 
and five (14%) a medium level of depression (HAM-D score > 18). No patients presented severe 
levels of depression (HAM-D score > 24). 
Among the type of disturbances, we found that the most impaired domains in HAM-D were “work 
activities” (N=10, 77%), “depressed mood” (N=8, 60%) and “early insomnia” (N=4, 27%) while in 
HAM-A there were “intellectual symptoms” (i.e., difficulty in concentration and poor memory) (N=6 
82%) and “tension” (N=4, 54%). 
At correlation analysis, better wellbeing was associated with better memory function (the sign of 
the correlation coefficient is negative because of the opposite interpretation scale of the two 
measurements): HAM-A test versus: digit span direct Spearman rho -0.472, p-value 0.004; digit 
span backward Spearman rho -0.597, p-value <0.001, Rey list direct Spearman rho 0.310, p-value 
0.075; Rey list recall: Spearman rho -0.432, p-value 0.011; HAM-D test versus: digit span direct 
Spearman rho -0.474, p-value 0.004; digit span backward Spearman rho -0.594, p-value <0.001, 
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Rey list direct Spearman rho 0.357, p-value 0.038; Rey list recall: Spearman rho -0.499, p-value 
0.003. 
 
Results of HrQoL assessment 
Table 5 displays the mean scores of the SF-36 assessments for each of the eight domains (by 
physical and mental components: physical activity (PA), role physically (RP), bodily pain (BP), 
general health (GH), vitality (VI), social functioning (SF), role emotional (ER) and mental health 
(MH). Acquired TTP patients showed lower normalized scores than the Italian reference sample14 
in all scales but physical activity. With regard to the physical components, the most impacted area 
was the physical role, with a mean score of 57 (median 55, range 40-85) and 11 patients (31%) 
with scores below 50. With regard to the mental components, emotional role was the most 
compromised, with a mean score of 43 (median 43, range 30-56) and 22 patients (63%) with 
scores below 50. Overall, the mental dimension was more affected than the physical dimension, 
with the mental component score MCS-36 (equivalent to the sum of MH, ER, SF and VI scores) 
lower than the physical component score PCS-36 (equivalent to the sum of PA, RP, BP and GH 
scores) by almost 60 points (mean difference -58.43, 95% CI [-71.49, -45.37]) and 15 (43% of 
patients pertaining to the MCS-36) versus 4 (11% of patients pertaining to the PCS-36) patients 
with scores below 50, the commonly accepted cut-off for an acceptable quality of life.15,16 
Finally, at correlation analysis, the better was the mental component score of the HrQoL survey, 
the better were the results of emotional wellbeing assessments, especially the anxiety evaluation 
(MCS-36 versus Hamilton Anxiety test: Spearman rho -0.358, p-value 0.035; MCS-36 versus 
Hamilton Depression test: Spearman rho -0.316, p-value 0.064). 
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DISCUSSION 
 
Neurological signs and symptoms of acute TTP are mainly transient, brief and resolve with 
remission of the acute phase. Our study demonstrates persisting neurological, neuropsychological, 
emotional and HrQoL impairments in TTP patients even years after the acute phase.  
During the remission phase, TTP patients showed a significant impairment in memory domains 
(direct, backward and deferred memory) when compared with the general population. This memory 
impairment was positively associated with the presence of neurological symptoms during the acute 
phase of the disease, as shown by the comparison between patients with and without neurological 
involvement during the first acute TTP event. Attention domains were also affected, but they were 
unrelated to neurological involvement during the acute phase. Our results are in line with previous 
findings by Kennedy et al. in 24 acquired TTP patients from the Oklahoma Registry, who 
performed significantly worse than the US reference population in both attention and memory 
functions.3,17 Conversely, at variance with our results, previous studies did not report an 
association of neurocognitive impairment with the occurrence of neurological manifestations at the 
time of the acute TTP event,3,18 although a trend towards a worse mental performance was 
detected in German patients with neurological symptoms compared with patients with no 
neurological symptoms (median of FLei mental performance score [IQR]: 45 [IQR 15-65] versus 31 
[IQR 13-40], Mann-Whitney U test p-value 0.193).18 It is worth-noticing that the prevalence of 
relapsing TTP cases were higher in patients with than without neurological symptoms during the 
first acute event (41% versus 8%). Unfortunately, the low sample size did not allow us to 
discriminate the effects of these two factors.  
Beside cognitive problems, we detected clinical anxiety and depression in 20% and 43% of 
interviewed patients. An even higher prevalence of depression symptoms in acquired TTP patients 
was reported in two US and one German cohorts (59%,17 81%,19 and 73%,18 respectively), which 
included also cases of major depression (29%,18 37%,19 and 14%18). However, a pre-existing 
diagnosis of depressive disorder was not an exclusion criterion in these studies, which may partly 
explain the differences in the observed prevalence. In our study, the results of anxiety and 
depression tests were negatively correlated with scores of neurocognitive assessments, indicating 
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that patients with symptoms of psychologic distress also had more pronounced cognitive defects. 
This is consistent with the findings of Falter and colleagues18, who reported a strong correlation 
between an impaired mental performance and the severity of depression in 84 TTP patients.  
It is interesting to compare our results with other cardiovascular and neurovascular diseases. High 
percentage of cognitive impairment were also found in patients after acute coronary syndrome 
(16% of patients)20, stroke (one-third of the sample examined),21 and after TIA (more than a third of 
patients).22 After TIA, also depressive symptoms were found as prevalent as 34%.23 However, 
there are important differences between these studies and ours. First, the evaluation of cognitive 
decline and depression were generally made during the acute phase and in patients older than 
ours.23 Second, the literature mainly highlights a major deterioration at the level of functional 
abilities in daily life activities, especially in stroke patients. Finally, different tests were performed 
and different cognitive domains (e.g., language) evaluated, making any comparison difficult. We 
also found an overall impaired quality of life compared with the general population. In the HrQoL 
domains, mental components were more impaired than physical components, suggesting that the 
condition determines a considerable emotional burden, probably related to its course of intermittent 
relapse and remission phases. Indeed, the HrQoL mental domain was negatively affected by the 
presence of clinical anxiety and depression in our patients. Our findings are consistent with those 
of Lewis et al.2 and Cataland et al.24 although they reported a greater impact of acquired TTP on 
the physical component of the HrQoL,2 and on both the mental and the physical component.24 
We believe that our findings have clinical relevance for the management of TTP patients. 
Clinicians should be aware of the association between neurological manifestations during the 
acute TTP episodes and long-term impaired neuropsychological abilities. They should put attention 
on signs and symptoms of neurological impairment during the remission phase and consider early 
signs of anxiety and depression in order to improve the quality of life of TTP patients. 
Our study has limitations. First, the neurocognitive and emotional status of the patients and their 
quality of life before their first episode of TTP was not objectively evaluated. However, patients did 
perceive and referred at the time of the psychological consultation a worsening of their conditions 
after TTP diagnosis. Second, the evaluation of neurological and cognitive functions abnormalities 
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observed in TTP patients in the remission phase and far from the clinical manifestations of acute 
TTP were not supported by instrumental neuro-functional analysis such as functional magnetic 
resonance imaging, which might be needed to assess the aforementioned alterations at the 
organic level. Third, we included patients with a history of a single acute TTP event but also 
patients with relapsing TTP, rendering our study population heterogeneous (in order to exclude 
potential comorbidities only primary TTP patients should be evaluated). However, the occurrence 
of multiple TTP episodes was never found to be associated with neurocognitive, emotional or 
HrQoL assessments in any previous study. 3,17,18,24 Fourth, the tests performed to evaluate clinical 
anxiety and depression, despite being well-validated tools, can only be suggestive of a psychiatric 
diagnosis, which indeed can only be confirmed by a proper psychiatric interview. Fifth, despite the 
relatively large sample size for a rare disease, numbers in some analyses are small, leading to 
statistical uncertainty and wide confidence intervals. This is a problem of any study in the field of 
rare diseases, and stimulate more efforts to promote collaboration between centers. Finally, the 
design of our study is cross-sectional and, thus cannot provide risk estimates and data about 
predictive factors. On the other hand, as far as we know, our study is the most comprehensive 
investigation on TTP patients, including clinical, cognitive, emotional and HrQoL assessment. 
In conclusion, we demonstrated that, despite successful treatment with plasma exchange and 
immunosuppressive therapy in the acute stage of the disease, patients with TTP suffer from 
long-term neurological sequelae even years after the acute phase. TTP patients with neurological 
involvement at the first acute episode seem to be at higher risk of developing memory dysfunction. 
Furthermore, TTP patients have increased levels of anxiety and depression, which negatively 
affect their quality of life. A faster improvement of the acute state of the disease by novel drugs 
might have a role in this process and further studies are required to solve this question. 
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TABLES 
 
Table 1. Demographic and clinical characteristics of 35 TTP patients included in the study. 
Clinical and laboratory data pertain the first acute TTP episode. 
 
Characteristics TTP patients (n=35) 
Demographic data 
 
Male, n (%)  8 (23) 
Caucasian, n (%) 34 (97) 
Age at TTP onset, years, median (IQR) 41 (35-48) 
Age at neuropsychological evaluation, years, median (IQR)* 45 (39-55) 
Mean school level, years 13 
Job status – workers, n (%) 30 (77) 
Clinical characteristics at the first acute TTP episode 
 
Neurological involvement, n (%) 22 (63) 
Platelet count, x 109/l, median (IQR)† 13 (8-27) 
Hemoglobin, g/dl, median (IQR)† 7.8 (6.8-10.0) 
Number of PEX to attain remission, median (IQR)† 11 (6-20) 
Laboratory parameters close to the neuropsychological evaluation† 
 
Platelet count, x 109/l, median (IQR) 251 (212-297) 
Hemoglobin, g/dl, median (IQR) 13.4 (12.8-14.3) 
ADAMTS13 activity close to neuropsychological evaluation† 
 
Normal (45-138%), n (%) 16 (47) 
Moderately reduced (10-45%), n (%) 12 (35) 
Severely reduced (<10%), n (%) 6 (18) 
 
At the time of neuropsychological evaluation, 10 (29%) of 35 patients had suffered from recurrent TTP 
bouts.*Neuropsychological evaluation was performed at a median time of 36 months (IQR 17-54) from the 
last acute TTP event. 
†Available in 33 (platelet count, hemoglobin and number of PEX to remission at first acute TTP episode), 34 
(ADAMTS13 activity close to neuropsychological evaluation) and 31 subjects (platelet count and hemoglobin 
close to the neuropsychological evaluation). 
Abbreviations: IQR, interquartile range; PEX, plasma exchange; TTP, thrombotic thrombocytopenic purpura. 
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Table 2. Descriptive statistics of neuropsychological tests in acquired TTP patients and 
mean values of the Italian general population. 
 
Test TTP patients 
Mean (SD) 
General population 
Mean 
Mean difference 
(95%CI) 
Memory       
Digit span 
(direct) 5.74 (1.12) 7.00 -1.26 (-1.64, -0.87) 
Digit span 
(backword) 4.51 (1.54) 6.00 -1.49 (-2.02, -0.96) 
Rey word list 
(direct)* 26.37 (7.74) 32.20 -5.87 (-8.57, -3.17) 
Rey word list 
(deferred)* 4.03 (1.86) 5.70 -1.67 (-2.32, -1.02) 
Attention       
Trail making A, 
seconds 34.37 (15.1) 45.00 -10.63 (-15.81, -5.44) 
Trail making B, 
seconds 214.09 (51.99) 149.00 65.09 (47.23, 82.94) 
 
In memory tests a higher score indicates a better performance, in attention tests a lower score indicates a 
better performance. 
At the time of neuropsychological evaluation, 10 (29%) of 35 patients had suffered from recurrent TTP 
bouts.*Available in 34 TTP patients. 
Abbreviations: CI, confidence interval; SD, standard deviation; TTP, thrombotic thrombocytopenic purpura. 
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Table 3. Descriptive statistics of neuropsychological tests in acquired TTP patients with 
and without neurological manifestations at onset of the first acute TTP event. 
 
Test 
Neurological involvement at first acute 
TTP event Mean difference 
(95%CI) 
Present (n=22) Absent (n=13) 
Memory, mean (SD)       
Digit span (direct) 5.45 (1.14) 6.23 (0.93) -0.78 (-1.54, -0.02) 
Digit span 
(backword) 4.18 (1.59) 5.08 (1.32) -0.90 (-1.96, 0.17) 
Rey word list 
(direct)* 25.36 (7.73) 27.89 (7.80) -2.54 (-8.11, 3.04) 
Rey word list 
(deferred)* 3.50 (1.92) 4.89 (1.44) -1.39 (-2.65, -0.13) 
Attention, mean (SD)       
Trail making A, 
seconds 37.18 (16.26) 29.62 (12.00) 7.57 (-3.01, 18.14) 
Trail making B, 
seconds 207.82 (49.91) 224.69 (55.71) -16.87 (-53.95, 20.20) 
 
In memory tests a lower score indicates a worse performance, in attention tests a higher score indicates a 
better performance. 
At the time of neuropsychological evaluation, 9 out of 22 (41%) and 1 out of 13 (8%) patients with and 
without neurological involvement at the first acute TTP event had suffered from recurrent TTP bouts, 
respectively. 
*Available in 34 TTP patients. 
Abbreviations: CI, confidence interval; SD, standard deviation; TTP, thrombotic thrombocytopenic purpura. 
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Table 4. Descriptive statistics of neuropsychological tests in acquired TTP patients with 
and without ADAMTS13 deficiency next to the psychological evaluation. 
 
Test 
ADAMTS13 activity during remission Mean difference 
(95%CI) <45% (n=18) ≥45% (n=16) 
Memory, mean (SD)      
Digit span (direct) 6.06 (1.00) 5.50 (1.16) 0.56 (-0.20, 1.31) 
Digit span 
(backward) 4.61 (1.79) 4.50 (1.27) 0.11 (-0.98, 1.21) 
Rey word list 
(direct)* 27.22 (7.72) 26.09 (7.65) 1.13 (-4.33, 6.59) 
Rey word list 
(deferred)* 4.44 (1.67) 3.73 (2.02) 0.72 (-0.59, 2.02) 
Attention, mean (SD)      
Trail making A, 
seconds 32.06 (13.39) 36.94 (17.32) -4.88 (-15.62, 5.87) 
Trail making B, 
seconds 209.89 (58.93) 220.94 (45.19) -11.05 (-48.09, 26.00) 
 
In memory tests a lower score indicates a worse performance, in attention tests a higher score indicates a 
better performance. 
At the time of neuropsychological evaluation, 5 out of 18 (28%) and 5 out of 16 (31%) patients with and 
without ADAMTS13 deficiency next to the visit had suffered from recurrent TTP bouts, respectively. 
*Available in 34 TTP patients. 
Abbreviations: CI, confidence interval; SD, standard deviation. 
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Table 5. Descriptive statistics of HRQoL components in acquired TTP patients and in Italian reference individuals. 
 
Test 
TTP patients (n=35) General population (n=2031) 
Mean difference (95%CI) 
mean (SD) N with score<50 (%) mean (SD) 
Physical domain 
    
Physical activity 81.40 (15.37) 2 (6) 84.46 (23.18) -3.06 (-8.43 to 2.31) 
Limitation 
physical role 56.77 (13.04) 11 (31) 78.21 (35.93) -21.44 (-26.17 to -16.72) 
Pain 62.20 (13.92) 5 (14) 73.67 (27.65) -11.47 (-16.39 to -6.55) 
General health 59.91 (11.54) 5 (14) 65.22 (22.18) -5.31 (-9.38 to -1.24) 
PCS-36 260.29 (44.63) 4 (11)* NA NA 
Mental domain 
    
Vitality 52.46 (12.85) 13 (37) 61.89 (20.69) -9.43 (-13.93 to -4.93) 
Social activity 54.26 (8.60) 7 (20) 77.43 (23.34) -23.17 (-26.28 to -20.06) 
Limitation 
emotional role 42.69 (8.76) 22 (63) 76.16 (37.25) -33.47 (-36.86 to -30.08) 
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Mental health 52.46 (5.45) 4 (11) 66.59 (20.89) -14.13 (-16.20 to -12.06) 
MCS-36 201.86 (23.84) 15 (43)* NA NA 
 
At the time of neuropsychological evaluation, 10 (29%) of 35 patients had suffered from recurrent TTP bouts. 
*Being PCS-36 and MCS-36 the weighted sum of the original scales of the SF-36, this number indicates patients with a score below 200. 
Abbreviations: CI, confidence interval; NA, not available; SD, standard deviation; MCS-36, mental component summary (MCS) of the Short Form (36) Health Status 
Questionnaire (SF36); PCS-36, physical component summary (PCS) of the Short Form (36) Health Status Questionnaire (SF36); TTP, thrombotic thrombocytopenic 
purpura. 
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SUPPLEMENTARY DATA 
 
Table S1. Enrolment criteria. 
 
 
 Patient characteristics 
Inclusion criteria (a) diagnosis of acquired TTP* 
(b) 18 years of age or older at the time of enrolment 
(c) adequate Italian language for the purpose of a valid psychometric testing 
Exclusion criteria (a) presence of severe neurological or psychiatric diseases before the onset 
of TTP 
(b) drug or alcohol-abuse possibly impacting on quality of life and 
neuropsychological tests 
 
* Acquired TTP was defined by at least one episode of thrombocytopenia and microangiopathic 
hemolytic anemia, with exclusion of alternative explanations,1 and by evidence of severe ADAMTS13 
deficiency (i.e., < 10% activity) in at least one plasma sample collected during the acute episode or 
disease remission, and/or by normalization of ADAMTS13 activity levels in the remission phase. 
ADAMTS13 activity was measured using a modified FRETS-VWF73 or CBA assay.2 
  
Table S2. Psychological measures. 
 
 
Assessment Goal Test name Administration Scoring 
Cognitive 
measure 
Short 
memory, 
direct 
memory 
Digit span3 List of numbers that one has to 
repeat in correct order 
immediately after presentation. 
Cognitive tests are standardized measures 
with population-based normative data that 
allow the examiner to evaluate a patient's 
performance with an appropriate group of 
reference (e.g., those of the same age group). 
Normative data are generally gathered on 
typically healthy subjects who are free from 
diagnosed cognitive dysfunctions, mental 
illness, disability or neurological disorders that 
could affect cognitive performance (all these 
variables cannot be controlled using a generic 
control group). Data are typically gathered on 
samples that reflect the broad demographic 
characteristics of the country of reference 
including factors such as age, and educational 
status.6 
 
 
 
Each subject’s raw score on each test was 
converted to a standardized score based on 
normative data generated from the value of 
the normal population according to the 
subject’s age and education level, as 
appropriate. Standardized scores of TTP 
patients were then compared with 
norm-referenced data from the Italian 
population.7-9 
Short 
memory; 
backward 
memory 
Digit span 
backward3 
List of numbers that one has to 
repeat in reverse order 
immediately after presentation. 
Immediate 
memory; 
deferred 
memory 
Word Rey 
List 
(direct and 
indirect)4 
Word-list memory task in which 
15 unrelated words are 
presented orally over three 
consecutive learning trials: the 
participant is asked to recall as 
many words as possible, after 
each presentation (direct score) 
and after 15 minutes (recall 
score). 
Sustained 
attention, 
focused 
attention 
Trail Making 
Test A5 
Patient is instructed to connect a 
set of 25 dots of numbers as fast 
as possible while still maintaining 
accuracy. 
Sustained 
attention, 
divided 
attention 
Trail Making 
Test B5 
Patient is instructed to connect a 
set of numbers and letters as fast 
as possible while still maintaining 
accuracy. 
Emotional 
wellbeing 
Anxiety Hamilton 
Anxiety 
Rating 
Scale10 
Psychologist-driven interview 
consisting of 14 items, each 
defined by a series of symptoms, 
and measures both psychic 
anxiety (mental agitation and 
psychological distress) and 
somatic anxiety (physical 
complaints related to anxiety). 
Each item is scored on a scale of 0 (not 
present) to 4 (severe), where ≤ 13 indicates 
absence of the disorder, 14-17 mild severity, 
18-24 moderate severity and ≥ 25 severe 
anxiety.10 
Depression Hamilton 
Depression 
Rating 
Scale11 
Psychologist-driven interview 
consisting of 17 items, each 
defined by a series of symptoms, 
and measures associated with 
depression (e.g. insomnia, 
hyperphagia). 
The score varies from ≤ 7 (absence of 
depression), 8-17 (mild depression), 18-24 
(medium depression) and ≥ 25 (severe 
depression).11 
Health-related 
quality of life 
(HrQoL) 
HrQoL SF-3612,13 Self-report scale evaluating 8 
dimensions: physical activity 
(PA), role physically (RP), bodily 
pain (BP), general health (GH), 
vitality (VI), social functioning 
(SF), role emotional (ER) and 
mental health (MH). 
Each scale is directly transformed into a 0-100 
scale on the assumption that each question 
carries equal weight (min-max: 0-100). To aid 
interpretation, norm-based scoring has been 
introduced for the SF-36, setting the general 
mean at 50 and the standard deviation (SD) 
at 10 for all scales, with higher scores 
indicating better health (i.e., a score of zero is 
equivalent to maximum disability and a score 
of 100 is equivalent to the best health status 
perceived).14 
Each subject’s raw score on each test was 
converted to a standardized score based on 
normative data generated from the value of 
the normal population according to the 
subject’s age and education level, as 
appropriate.14, 15 Standardized scores of TTP 
patients were compared with norm referenced 
data from the Italian population.15 
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